Articles with public access mandates - Jianjun ZhangLearn more
Not available anywhere: 9
Review
Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer
G Schvartsman, SA Peng, G Bis, JJ Lee, MFK Benveniste, J Zhang, ...
Lung cancer 112, 90-95, 2017
Mandates: US National Institutes of Health
Review
Activation of PI3K/AKT pathway is a potential mechanism of treatment resistance in small cell lung cancer
Y Jin, Y Chen, H Tang, X Hu, SM Hubert, Q Li, D Su, H Xu, Y Fan, X Yu, ...
Clinical Cancer Research 28 (3), 526-539, 2022
Mandates: National Natural Science Foundation of China
Review
Sorafenib in non-small cell lung cancer
J Zhang, KA Gold, E Kim
Expert opinion on investigational drugs 21 (9), 1417-1426, 2012
Mandates: US National Institutes of Health
Review
Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation
Y Jin, H Bao, X Le, X Fan, M Tang, X Shi, J Zhao, J Yan, Y Xu, K Quek, ...
Oncogene 39 (9), 1846-1859, 2020
Mandates: National Natural Science Foundation of China, National Institute for Health …
Review
Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma
X Liu, F Wang, C Xu, X Chen, X Hou, Q Li, P Li, Z Xie, Y Liu, L Chang, ...
Oncogene 40 (4), 821-832, 2021
Mandates: National Natural Science Foundation of China
Review
Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy
P Tian, H Zeng, L Ji, Z Ding, L Ren, W Gao, Z Fan, L Li, X Le, P Li, ...
Lung Cancer 160, 50-58, 2021
Mandates: National Natural Science Foundation of China
Review
Female gender predicts augmented immune infiltration in lung adenocarcinoma
C Behrens, P Rocha, ER Parra, L Feng, J Rodriguez-Canales, LM Solis, ...
Clinical Lung Cancer 22 (3), e415-e424, 2021
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Review
Clinical effectiveness and safety of anti-PD-(L) 1 therapy among older adults with advanced non-small cell lung cancer
M Altan, EK Singhi, M Worst, BW Carter, CH Leung, JJ Lee, CJ Presley, ...
Clinical Lung Cancer 23 (3), 236-243, 2022
Mandates: US National Institutes of Health
Review
Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection
N Deboever, DJ McGrail, Y Lee, HT Tran, KG Mitchell, MB Antonoff, ...
Lung Cancer 164, 69-75, 2022
Mandates: US National Institutes of Health
Available somewhere: 143
Review
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ...
Cancer discovery 8 (7), 822-835, 2018
Mandates: US National Institutes of Health, V Foundation, USA
Review
Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional …
DR Gomez, C Tang, J Zhang, GR Blumenschein Jr, M Hernandez, JJ Lee, ...
Journal of Clinical Oncology 37 (18), 1558-1565, 2019
Mandates: US National Institutes of Health
Review
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic …
DR Gomez, GR Blumenschein, JJ Lee, M Hernandez, R Ye, DR Camidge, ...
The lancet oncology 17 (12), 1672-1682, 2016
Mandates: US National Institutes of Health
Review
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
J Zhang, J Fujimoto, J Zhang, DC Wedge, X Song, J Zhang, S Seth, ...
Science 346 (6206), 256-259, 2014
Mandates: US National Institutes of Health, Research Foundation (Flanders), Cancer …
Review
Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic …
F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ...
Cancer discovery 5 (8), 860-877, 2015
Mandates: US National Institutes of Health, V Foundation, USA
Review
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
T Cascone, WN William Jr, A Weissferdt, CH Leung, HY Lin, A Pataer, ...
Nature medicine 27 (3), 504-514, 2021
Mandates: US National Institutes of Health
Review
Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma
Y Zhou, D Yang, Q Yang, X Lv, W Huang, Z Zhou, Y Wang, Z Zhang, ...
Nature communications 11 (1), 6322, 2020
Mandates: National Natural Science Foundation of China, Cancer Research UK, European …
Review
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
X Le, S Puri, MV Negrao, MB Nilsson, J Robichaux, T Boyle, JK Hicks, ...
Clinical Cancer Research 24 (24), 6195-6203, 2018
Mandates: US National Institutes of Health
Review
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer
CA Stewart, CM Gay, Y Xi, S Sivajothi, V Sivakamasundari, J Fujimoto, ...
Nature cancer 1 (4), 423-436, 2020
Mandates: US Department of Defense, US National Institutes of Health
Review
MuSE: accounting for tumor heterogeneity using a sample-specific error model improves sensitivity and specificity in mutation calling from sequencing data
Y Fan, L Xi, DST Hughes, J Zhang, J Zhang, PA Futreal, DA Wheeler, ...
Genome biology 17, 1-11, 2016
Mandates: US National Institutes of Health
Review
Structure-based classification predicts drug response in EGFR-mutant NSCLC
JP Robichaux, X Le, RSK Vijayan, JK Hicks, S Heeke, YY Elamin, HY Lin, ...
Nature 597 (7878), 732-737, 2021
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Publication and funding information is determined automatically by a computer program